Caxton »

Sab Biotherapeutics shares owned by Caxton

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Caxton from 13F filings

Historical chart of Caxton investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Caxton consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Caxton

Quarter filed Position value Share count Share price at filing
2025-09-30 $22k 11k 2.01

More positions owned by Caxton

Rezolute Com New (RZLT)
Spdr Gold Tr Gold Shs (GLD)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
Mind Medicine Mindmed Com New (MNMD)
Enliven Therapeutics (ELVN)
Compass Therapeutics (CMPX)
Bicara Therapeutics (BCAX)
Kyverna Therapeutics (KYTX)
Lexeo Therapeutics (LXEO)
Inhibikase Therapeutics Com New (IKT)
Sab Biotherapeutics Com New (SABS)
Context Therapeutics (CNTX)

View all positions for Caxton

Top funds holding Sab Biotherapeutics

Vivo Capital
RA Capital Management
Commodore Capital
Woodline Partners
Sessa Capital IM
BVF
Sphera Funds Management
Vanguard Group
HB Wealth Management
AWM Investment Company
Geode Capital Management
Renaissance Technologies
Pathstone Holdings
Virtu Financial
Kovitz Investment Group Partners

View all funds holding Sab Biotherapeutics